Iovance Biotherapeutics Inc (NASDAQ: IOVA): The Best-Of-Breed For Investing?

Currently, there are 256.14M common shares owned by the public and among those 219.99M shares have been available to trade.

However, the script later moved the day high at 15.29, down -2.96%. The company’s stock has a 5-day price change of -5.23% and 69.37% over the past three months. IOVA shares are trading 69.37% year to date (YTD), with the 12-month market performance up to 123.90% higher. It has a 12-month low price of $3.21 and touched a high of $18.33 over the same period. IOVA has an average intraday trading volume of 9.71 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.36%, 11.00%, and 76.56% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 67.26% of the company’s 256.14M shares outstanding.

It has a market capitalization of $3.85B and a beta (3y monthly) value of 0.59. The earnings-per-share (ttm) stands at -$1.89. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.93% over the week and 6.73% over the month.

Earnings per share for the fiscal year are expected to increase by 30.65%, and 41.97% over the next financial year.

Looking at the support for the IOVA, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on November 20, 2023, with the firm’s price target at $12. Barclays coverage for the Iovance Biotherapeutics Inc (IOVA) stock in a research note released on September 18, 2023 offered a Overweight rating with a price target of $18. Wells Fargo was of a view on May 30, 2023 that the stock is Overweight, while Wells Fargo gave the stock Equal Weight rating on March 27, 2023, issuing a price target of $11. Piper Sandler on their part issued Overweight rating on January 27, 2023.

Most Popular

Related Posts